Dr. Joaquín Míchel Joins DHR Health Urology Institute, Expanding Access to Care

Translate to Spanish or other 102 languages!

DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Joaquin Michel to its esteemed team of urologists at the DHR Health Urology Institute. Courtesy images.
DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Joaquin Michel to its esteemed team of urologists at the DHR Health Urology Institute. Courtesy images.
- Advertisement -

EDINBURG, Texas – DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Joaquin Michel to its esteemed team of urologists at the DHR Health Urology Institute. Michel is passionate about improving patients’ quality of life and is dedicated to providing compassionate, comprehensive care for a wide range of urologic conditions. He treats urinary and pelvic conditions such as kidney stones, prostate enlargement, and cancers of the kidney, bladder, and prostate, with expertise in minimally invasive surgical techniques and evidence based treatment approaches.

“We are thrilled to welcome Dr. Michel to our Urology Institute,” said Marissa Castañeda, senior executive vice president at DHR Health. “His outstanding training, research background, and commitment to culturally responsive care makes him an excellent addition to our team as we continue to expand advanced urologic services for our community.”

Michel earned his Bachelor of Science in Physiology from the University of California at Davis. He went on to earn his medical degree from the David Geffen School of Medicine at UCLA in Los Angeles, California. Following medical school, he completed a general surgery internship and urology residency at Mount Sinai Medical Center in Miami Beach, Florida.

- Advertisement -

Throughout his career, Michel has been active in research, authoring and co-authoring numerous peer-reviewed publication on topics including prostate cancer, bladder cancer, renal mass biopsy, and urologic oncology outcomes. He has presented his work at national and international conferences, including the American Urological Association and the Society of Urologic Oncology.

In addition to his clinical and research expertise, Michel has a strong background in teaching and mentorship, having served as a tutor for physician assistant and nursing students as well as a USMLE Step 1 tutor for medical students. His dedication to culturally responsive care has been recognized through several merit-based awards, including the Oliver Golsmith Scholarship for Culturally Responsive Care and the Dean’s Leadership in Health and Science Scholarship from UCLA.

“I value being a supportive guide during vulnerable moments and helping patients regain confidence and control over their health,” said Michel. “It is a deep honor for me to return and serve a community that reflects the one that helped shape me. I am fully committed to providing the highest quality urologic care possible, always placing your safety, comfort, and quality of life in the center of my approach”

Michel is now accepting new patients at the DHR Health Urology Institute, located at 2603 Michelangelo Drive in Edinburg. To schedule an appointment, please call (956) 362-8767. DHR Health accepts a variety of health insurance plans, as well as Medicare and Medicaid.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.

DHR Health Burn Surgeon Urges Public to Avoid Preventable Risks

Many of the most serious burn and trauma injuries can be prevented by avoiding unnecessary risks, according to Dr. R. Dewayne Edwards, chief burn surgeon, surgical critical care and trauma surgeon at DHR Health, who said public awareness and timely medical care remain essential to improving patient outcomes.
- Advertisement -